Biogen’s Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

 Biogen’s Gosuranemab (BIIB092) Fails to Meet its Primary Endpoint in P-II TANGO Study for Alzheimer Disease

Shots:

  • The P-II TANGO study evaluating the safety & efficacy of gosuranemab vs PBO in 654 patients aged 50–80 yrs with MCI due to AD or with mild AD for 78 wks across 97 sites, followed by a dose-blind long term extension period
  • The trial did not meet its 1EPs i.e change from baseline on CDR-SB @ 78 wks., no treatment benefit was observed on exploratory efficacy EPs includes ADAS-Cog 13, ADCS-ADL, MMSE & FAQ. Additionally, the therapy was well-tolerated overall & safety outcomes were consistent with previous studies of gosuranemab
  • The company has decided to discontinue the further clinical development of gosuranemab while investigation of additional data include CSF biomarkers are ongoing

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: The Business Journals

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post